Rob van Maanen

Key Insights into Gut Alterations in Metabolic Syndrome

The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder ( SYNERGY study)

Patient‐reported outcomes from SYNERGY, a randomized, double‐blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients